Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Xencor logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised its Xencor price target from $21 to $37 but maintained a neutral rating; the new target implied 7.82% upside from the prior close.
  • Analyst sentiment overall was more positive: Xencor had a “Moderate Buy” consensus rating and a $44 average price target, with six Buy and one Strong Buy ratings among 11 analysts.
  • Xencor reported quarterly EPS of $0.50, beating the consensus estimate of a $0.33 loss, while revenue of $116.52 million exceeded expectations and rose 453.3% year over year.
  • MarketBeat previews the top five stocks to own by December 1st.

Xencor (NASDAQ:XNCR - Get Free Report) had its price objective boosted by stock analysts at JPMorgan Chase & Co. from $21.00 to $37.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a "neutral" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 7.82% from the stock's previous close.

Other equities analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Xencor from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. Wells Fargo & Company raised their target price on Xencor from $30.00 to $44.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 27th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a research report on Monday, September 21st. Raymond James Financial upped their price target on Xencor from $40.00 to $46.00 and gave the company a "strong-buy" rating in a research report on Tuesday, September 1st. Finally, Barclays set a $45.00 price objective on shares of Xencor and gave the company an "overweight" rating in a research report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xencor currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.

Read Our Latest Stock Analysis on Xencor

Xencor Trading Down 0.2%

Shares of XNCR traded down $0.07 during midday trading on Thursday, hitting $34.31. The stock had a trading volume of 324,752 shares, compared to its average volume of 1,060,271. Xencor has a fifty-two week low of $10.38 and a fifty-two week high of $40.60. The business has a 50-day simple moving average of $27.89 and a two-hundred day simple moving average of $18.44. The firm has a market cap of $2.57 billion, a P/E ratio of -21.56 and a beta of 0.78.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.83. Xencor had a negative net margin of 58.79% and a negative return on equity of 21.28%. The business had revenue of $116.52 million for the quarter, compared to the consensus estimate of $63.00 million. During the same quarter last year, the company posted ($0.08) earnings per share. Xencor's quarterly revenue was up 453.3% on a year-over-year basis. On average, analysts expect that Xencor will post -2.61 earnings per share for the current fiscal year.

Insider Transactions at Xencor

In other Xencor news, Director Richard Ranieri sold 81,252 shares of the firm's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $39.25, for a total transaction of $3,189,141.00. Following the completion of the transaction, the director directly owned 18,514 shares of the company's stock, valued at $726,674.50. This trade represents a 81.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.08% of the stock is currently owned by corporate insiders.

Institutional Trading of Xencor

Hedge funds have recently modified their holdings of the company. Aquatic Capital Management LLC bought a new position in shares of Xencor in the 3rd quarter valued at about $406,000. Goldman Sachs Group Inc. grew its position in shares of Xencor by 45.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,413,888 shares of the biopharmaceutical company's stock valued at $35,277,000 after acquiring an additional 445,110 shares during the period. Toronto Dominion Bank boosted its stake in shares of Xencor by 688.5% during the 3rd quarter. Toronto Dominion Bank now owns 3,871,297 shares of the biopharmaceutical company's stock worth $96,589,000 after acquiring an additional 3,380,297 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Xencor during the third quarter worth approximately $25,000. Finally, Palumbo Wealth Management LLC grew its position in Xencor by 0.8% during the third quarter. Palumbo Wealth Management LLC now owns 37,832 shares of the biopharmaceutical company's stock worth $944,000 after buying an additional 292 shares in the last quarter.

Xencor Company Profile

(Get Free Report)

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company's XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets.

Further Reading

Analyst Recommendations for Xencor (NASDAQ:XNCR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Xencor Right Now?

Before you consider Xencor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.

While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines